Crossmark

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS

Crossref DOI link: https://doi.org/10.1186/s40880-016-0154-7

Published Online: 2016-10-28

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pang, Xiufeng https://orcid.org/0000-0002-4271-8710
Liu, Mingyao
Funding

Funding for this research was provided by:

the National Natural Science Foundation of China (81672758)

the Science and Technology Commission of Shanghai Municipality (16ZR1410400)

the Science and Technology Commission of Shanghai Municipality (14DZ2270100)

the Fundamental Research Funds for the Central Universities (78260029)